EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating Epithelial Tumor Cells (CETC/CTC) in Prostate Cancer: Potential Prognostic Marker for the Risk of Recurrence During Radiotherapy

Dorothea Schott, Monika Pizon iD, Sonia Drozdz, Irina Mäurer, Georg Wurschi iD, Katharina Pachmann, Matthias Mäurer iD

International Journal of Molecular Sciences · 12.02.2025 · 26 (4) · 1548

DOI: 10.3390/ijms26041548 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.02.2025. Verfasst von Dorothea Schott und 6 weiteren Autor:innen. Beteiligte Einrichtung: Transfusion Medicine Center Bayreuth, Kurpromenade 2, 95448 Bayreuth, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplastic Cells, Circulating, Neoplasm Recurrence, Local, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Interdisciplinary Center of Clinical Research of the Medical Faculty Jena, Else-Kroner-Fresenius-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer is a leading cause of cancer-related mortality in men, with radiotherapy (RT) playing a pivotal role in treatment. However, reliable biomarkers for assessing relapse risk following RT remain scarce. This study aimed to evaluate circulating epithelial tumor cells (CETC/CTC) as potential biomarkers for assessing relapse risk in prostate cancer patients undergoing RT. Peripheral blood samples were collected from 52 prostate cancer patients, and CETC/CTC were detected using the EpCAM surface marker. Patients received definitive, adjuvant, or salvage RT, and CETC/CTC counts were measured before, at mid-treatment, and at the end of RT. The association between changes in CETC/CTC counts and relapse risk was examined. CETC/CTC were detected in 96% of patients prior to RT. A significant reduction in CETC/CTC counts during RT, particularly in patients who had undergone surgery, was associated with a lower relapse risk. In contrast, an increase in CETC/CTC counts during or after RT was associated with a higher relapse risk (hazard ratio = 8.8; p = 0.002). Furthermore, 36% of patients receiving adjuvant RT and 14% of those receiving definitive RT relapsed, with a higher risk observed in patients showing increasing CETC/CTC counts during RT. Among patients receiving salvage RT, 18% relapsed, though changes in CETC/CTC counts were less significantly associated with relapse. Monitoring CETC/CTC levels during RT offers important prognostic insights into relapse risk in prostate cancer patients. While changes in CETC/CTC counts correlated with relapse, PSA levels measured during the study did not reliably reflect relapse risk in this cohort. CETC/CTC shows promise as a prognostic marker, though further studies are required to validate its clinical superiority over PSA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsNeoplastic Cells, CirculatingNeoplasm Recurrence, LocalBiomarkers, TumorHumansMaleAgedPrognosisMiddle AgedEpithelial Cell Adhesion MoleculeAged, 80 and over

Stichwörter der Autor:innen

PSAcirculating epithelial tumor cellsprognostic biomarkerprostate cancerradiotherapyrisk stratification

Substanzen

Biomarkers, TumorEpithelial Cell Adhesion Molecule

Autor:innen und Institutionen

  • Transfusion Medicine Center Bayreuth, Kurpromenade 2, 95448 Bayreuth, Germany.
  • Department of Radiotherapy and Radiation Oncology, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany.
  • Department of Neurology, Neurooncology Center, University Hospital, Am Klinikum 1, 07747 Jena, Germany.
  • Clinician Scientist Program, Interdisciplinary Center for Clinical Research (IZKF), Jena Hospital, 07747 Jena, Germany.
  • Clinician Scientist Program OrganAge, Interdisciplinary Center for Clinical Research (IZKF), Jena Hospital, 07747 Jena, Germany.

ORCID-Profile: Monika Pizon, Georg Wurschi, Matthias Mäurer

Förderung

  • Deutsche Forschungsgemeinschaft
  • Interdisciplinary Center of Clinical Research of the Medical Faculty Jena
  • Else-Kroner-Fresenius-Stiftung

Zitieren

APA

Schott, D., Pizon, M., Drozdz, S., Mäurer, I., Wurschi, G., Pachmann, K., & Mäurer, M. (2025). Circulating Epithelial Tumor Cells (CETC/CTC) in Prostate Cancer: Potential Prognostic Marker for the Risk of Recurrence During Radiotherapy. International Journal of Molecular Sciences, 26(4), 1548. https://doi.org/10.3390/ijms26041548

Vancouver

Schott D, Pizon M, Drozdz S, Mäurer I, Wurschi G, Pachmann K, et al. Circulating Epithelial Tumor Cells (CETC/CTC) in Prostate Cancer: Potential Prognostic Marker for the Risk of Recurrence During Radiotherapy. International Journal of Molecular Sciences. 2025;26(4):1548. doi:10.3390/ijms26041548

BibTeX
@article{Schott2025,
  author = {Schott, Dorothea and Pizon, Monika and Drozdz, Sonia and Mäurer, Irina and Wurschi, Georg and Pachmann, Katharina and Mäurer, Matthias},
  title = {Circulating Epithelial Tumor Cells (CETC/CTC) in Prostate Cancer: Potential Prognostic Marker for the Risk of Recurrence During Radiotherapy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {4},
  pages = {1548},
  doi = {10.3390/ijms26041548}
}
Kostenlos starten →